Developing KETAMINE for near-rare and rare disorders via the 505(b)(2) pathway.

Commercializing KetAImine™ AI Discovery Platform to expand the Ketamine portfolio, enable earlier partnering, and fast-track 505(b)(2) NDA filings.​
OTCQB: PHRRF  |  CSE: PHRM

Press Releases

"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."

Subscribe for press releases

Connect With Us

PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario  Canada
M5C 1P1